To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Glucose Monitoring System Approved In U.S. URL: http://www.pslgroup.com/dg/4B3E2.htm Doctor's Guide December 4, 1997
SAN DIEGO, CA -- December 4, 1997 -- The United States Food and Drug Administration (FDA) has granted marketing clearance to LXN Corp.'s duet glucose control monitoring system. The patented duet system is the first product to combine fingerstick tests for both blood glucose and glycated protein (fructosamine) on one easy-to-use hand-held meter. Beginning in January, the product will be available as a self-test for persons with diabetes and also as a point-of-care tool for healthcare professionals. LXN's glycated protein test, sold under the tradename GlucoProtein(TM), measures overall glucose control for the previous two week period and is the first and only glycated protein test ever to be cleared for use outside the clinical laboratory. The company expects that its Duet System will be especially valuable to persons with type II diabetes, a group that the American Diabetes Association estimates to comprise more than 90 percent of the nearly 17 million Americans with diabetes. Persons with type II diabetes face the same risk of disease complications as those with type I, yet they are known to be poorly compliant with recommended test frequencies for both glucose and glycated protein. The GlucoProtein test is more sensitive than glycated hemoglobin (HbA1c) to recent changes in glucose control. The test measures the average of continuous glucose levels over the prior two-week period, whereas HbA1c indicates the average over a two to three month period. LXN also plans to aggressively market the Duet System as an in-office test to healthcare professionals. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.